24290-47-9

Basic information

• Product Name: 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl
• Synonyms: 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl;2-Methyl-1-phenylpropan-1-aMine hydrochloride
• CAS NO: 24290-47-9
• Molecular Formula: C₁₀H₁₅N*ClH
• Molecular Weight: 185.69374
• Mol File: 24290-47-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated), Water (Slightly)
• CAS DataBase Reference: 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl(24290-47-9)
• EPA Substance Registry System: 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl(24290-47-9)

Safety Data

• Hazardous Substances Data: 24290-47-9(Hazardous Substances Data)

Usage

Description

2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl, also known as α-Isopropylbenzylamine Hydrochloride, is an organic compound with amine functional groups. It is characterized by its chemical structure, which includes a phenyl group attached to a propane chain with a methyl group at the 2nd position and a hydrochloride ion. 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl is a versatile building block in the synthesis of various organic molecules.

Uses

Used in Pharmaceutical Industry:
2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl is used as an intermediate in the synthetic preparation of arylalkylamines. It serves as a key component in the production of various pharmaceutical compounds due to its ability to react with Grignard reagents to form phosphorylaldimines, which are important in the synthesis of complex organic molecules with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-METHYL-1-PHENYLPROPAN-1-AMINE-HCl is used as a starting material for the preparation of various organic compounds, including arylalkylamines. Its reactivity with Grignard reagents allows for the creation of a wide range of molecules with diverse properties and potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 180399-94-4 N-(Diethoxyphosphoryl)benzylideneimine 
• 611-70-1 phenyl isopropyl ketone 
• 72846-70-9 isopropyl phenyl ketoxime 

Downstream Products

• 56010-63-0 2,2-dimethyl-3-hydroxy-1-phenylpropan-1-one 

Relevant articles and documents

Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H2R and D3R

Even today, the role of the histamine H2 receptor (H2R) in the central nervous system (CNS) is widely unknown. In previous research, many dimeric, high-affinity and subtype-selective carbamoylguanidine-type ligands such as UR-NK22 (5, pKi = 8.07) were reported as H2R agonists. However, their applicability to the study of the H2R in the CNS is compromised by their molecular and pharmacokinetic properties, such as high molecular weight and, consequently, a limited bioavailability. To address the need for more drug-like H2R agonists with high affinity, we synthesized a series of monomeric (thio)carbamoylguanidine-type ligands containing various spacers and side-chain moieties. This structural simplification resulted in potent (partial) agonists (guinea pig right atrium, [35S]GTPγS and β-arrestin2 recruitment assays) with human (h) H2R affinities in the one-digit nanomolar range (pKi (139, UR-KAT523): 8.35; pKi (157, UR-MB-69): 8.69). Most of the compounds presented here exhibited an excellent selectivity profile towards the hH2R, e.g. 157 being at least 3800-fold selective within the histamine receptor family. The structural similarities of our monomeric ligands to pramipexole (6), a dopamine receptor agonist, suggested an investigation of the binding behavior at those receptors. The target compounds were (partial) agonists with moderate affinity at the hD2longR and agonists with high affinity at the hD3R (e.g. pKi (139, UR-KAT523): 7.80; pKi (157, UR-MB-69): 8.06). In summary, we developed a series of novel, more drug-like H2R and D3R agonists for the application in recombinant systems in which either the H2R or the D3R is solely expressed. Furthermore, our ligands are promising lead compounds in the development of selective H2R agonists for future in vivo studies or experiments utilizing primary tissue to unravel the role and function of the H2R in the CNS.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Synthesis of α-arylalkylamines by addition of Grignard reagents to N- (diethoxyphosphoryl)aldimines

Addition of organomagnesium bromides to N-(diethoxyphosphoryl) aldimines 1 carded out in tetrahydrofuran at 20-25°C affords diethyl N-alkyl- phosphoramidates 2a-w in high yields and spectroscopic purity. Deprotection of the latent amino groups in 2 results in the formation of α-arylalkylamine hydrochlorides 3a-w.